Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans : A Pharmacokinetic Study in Healthy Subjects Jose´ Alexandre S. Crippa, Antonio Waldo Zuardi, Jaime Eduardo Cecılio Hallak, Bruna Miyazawa, Sandra Aparecido Bernardo, Carmem Maria Donaduzzi, Silvane Guzzi, Wagner Alex Jann Favreto, Alline Campos, Maria Eugenia C. Queiroz, Francisco S. Guimaraes, Patrıcia Moura da Rosa Zimmermann, Letıcia Mello Rechia, Volnei Jose Tondo Filho, and Liberato Brum Junior Cannabis and Cannabinoid Research, 2019, Volume X, Number X DOI: 10.1089/can.2019.0024 Abstract Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy [...]
Lire la suiteComparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Δ9-Tetrahydrocannabinol Chris S. Breivogel, Jacob R. Wells, Amreen Jonas, Artik H. Mistry, Morgan L. Gravley, Rajul M. Patel, Brianna E. Whithorn, and Bonnie M. Brenseke Cannabis and Cannabinoid Research, 2019, Volume X, Number X DOI: 10.1089/can.2019.0003 Abstract Introduction : Synthetic cannabinoids (SCs) are commonly found in preparations used as recreational drugs. Although severe adverse health effects are not generally associated with cannabis use, a rising number of studies document seizures and even death after SC use. In this study, a mouse model is used to investigate the hypothesis that SCs are more [...]
Lire la suite2-Linoleoylglycerol Is a Partial Agonist of the Human Cannabinoid Type 1 Receptor that Can Suppress 2-Arachidonolyglycerol and Anandamide Activity Leanne Lu, Gareth Williams, and Patrick Doherty Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2019.0030 Abstract Introduction : The cannabinoid type 1 (CB1) receptor and cannabinoid type 2 (CB2) receptor are widely expressed in the body and anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are their best characterized endogenous ligands. The diacylglycerol lipases (diacylglycerol lipase alpha and diacyl-glycerol lipase beta) not only synthesize essentially all the 2-AG in the body but also generate other monoacylglycerols, including 2-linoleoylglycerol (2-LG). This lipid has been proposed to modulate endocannabinoid [...]
Lire la suiteReceptor-Enriched Analysis of functional connectivity by targets (REACT) : A novel, multimodal analytical approach informed by PET to study the pharmacodynamic response of the brain under MDMA Ottavia Dipasquale, Pierluigi Selvaggi, Mattia Veronese, Anthony S. Gabay, Federico Turkheimer, Mitul A. Mehta NeuroImage, 2019, 195, 252–260 https://doi.org/10.1016/j.neuroimage.2019.04.007 A B S T R A C T One of the main limitations of pharmacological fMRI is its inability to provide a molecular insight into the main effect of compounds, leaving an open question about the relationship between drug effects and haemodynamic response. The aim of this study is to investigate the acute effects of 3,4-methylene-dioxymethamphetamine (MDMA) on functional [...]
Lire la suitePsilocybin exerts distinct effects on resting state networks 1 associated with serotonin and dopamine in mice Joanes Grandjean, David Buehlmann, Michaela Buerge, Hannes Sigrist, Erich Seifritz, Franz X. Vollenweider, Christopher R. Pryce, Markus Rudin Preprint · September 2019 Doi : 10.1101/751255 Abstract Hallucinogenic agents have been proposed as potent antidepressants; this includes the serotonin (5-HT) receptor 2A agonist psilocybin. In human subjects, psilocybin alters functional connectivity (FC) within the default-mode network (DMN), a constellation of inter-connected regions that is involved in self-reference and displays altered FC in depressive disorders. In this study we investigated the effects of psilocybin on FC in the analogue of the [...]
Lire la suiteThe Role of MDMA Neurotoxicity in Anxiety Casey R. Guillot, Mitchell E. Berman and Brenton R. Abadie In : Neurotoxicity Syndromes, Chapter I ISBN: 978-1-60021-797-5 Editor: Linda R. Webster, pp. 1 - 36 © 2007 Nova Science Publishers, Inc. Abstract The drug 3,4-methylenedioxymethamphetamine (MDMA; Ecstasy) long has been considered a neurotoxin selective for serotonin (5-hydroxytryptamine; 5-HT) axons in rats and nonhuman primates. MDMA is also thought to have the potential to cause persistent serotonergic alterations in humans. Since the serotonin system is involved in the regulation of anxiety, researchers have proposed that recreational Ecstasy users may be at risk for the development of anxiety disorders and symptoms. [...]
Lire la suiteDu cannabis dans le PLFSS Le député Olivier Véran (LREM, Isère) va défendre un amendement introduisant une expérimentation du cannabis thérapeutique. © FOTOLIA_FABIOBERTI.IT Les choses se précisent. Après que l'Agence nationale de sécurité du médicament et des produits de santé (ANSM) a souscrit, début juillet 2019, aux propositions du comité scientifique spécialisé temporaire sur le cadre pratique de l’accès au cannabis à visée thérapeutique en vue d’une expérimentation en France, c'est désormais le cadre légal qui va être discuté à l'Assemblée nationale. Invité à l'antenne de RTL, le neurologue et député de la majorité, Olivier Véran, a ainsi expliqué qu'il allait présenter et défendre un amendement au projet de loi de financement de la sécurité sociale (PLFSS) pour 2020 visant à mettre en place, au plus vite, une expérimentation en milieu hospitalier. Selon ses dires, elle devrait concerner « environ 3 000 malades » qui seront « suivis par des [...]
Lire la suiteA History of Drug Use : Mind-Altering Drugs in Social Context Eric Shepperd January 21, 2017, 26 p. It seems that an intrinsic property of consciousness is a desire to alter itself. The natural world is full of tools for changing the functioning of the mind, and both humans and nonhuman animals have used many different drugs throughout history. Some are derived directly from plant or animal sources, while others are refined extracts, or synthesized by purely chemical methods. Many of the drugs in use today are applied primarily for physiologically therapeutic purposes, while others have primarily psychological components, or a combination thereof. Psychoactive [...]
Lire la suiteLa recherche sur les microdoses de substances psychédéliques. James Fadiman, Sophie Korbe et les « micro-doses » Vittorio Biancardi Chimères, 2017/1 N° 91 | pages 139 à148 Les programmes de recherche qui ont été menés légalement sur des dizaines de milliers de patients, à partir de la moitié du vingtième siècle, ont démontré qu’un usage soigneusement réduit de lsd peut se révéler efficace contre certaines psychopathologies, et bénéfique pour le développement personnel et spirituel. En outre, de récentes études ont mis en évidence que la prise de petites doses de lsd peut permettre entre autres une augmentation des capacités cognitives chez des sujets [...]
Lire la suiteLe microdosage de substances psychédéliques : bref historique et nouveaux axes de recherche Vittorio Biancardi Revue CIRCE, 2019, 11, Résumé Le micro-dosage est un phénomène social de plus en plus répandu parmi la communauté des consommateurs et consommatrices des substances dites psychédéliques. Il consiste une consommation d’un dixième de la dose typique de substance (principalement LSD ou Psilocybine) de façon fréquente, deux ou trois fois par semaine, pour améliorer les capacités cognitives ou comme auto-thérapie. L’analyse de ce phénomène est actuellement très fragmentaire et inconsistante, tant du point de vue des sciences humaines que du point de vue des sciences dites «dures». L’objectif de [...]
Lire la suite